Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
Chong Feng, Lening Zhang, Xin Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19

Showing 19 citing articles:

Mechanisms and functions of protein S-acylation
Francisco S. Mesquita, Laurence Abrami, Maurine E. Linder, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 6, pp. 488-509
Closed Access | Times Cited: 43
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Advanced Melanomas
Emma Wagner, Banafshé Larijani, Amanda Kirane
Surgical Oncology Clinics of North America (2025)
Closed Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025), pp. 155864-155864
Closed Access
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Xiaohui Ren, Lijuan Wang, Likun Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab
Sara Malih
American Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 14, Iss. 1, pp. 31-40
Open Access | Times Cited: 5
PD-L1 Expression in Receptor-Negative Breast Cancer Tissue
Ye. A LUKIANOV, Oleksandr Mushii, Mykhailo Krotevych, et al.
Experimental Oncology (2025) Vol. 46, Iss. 4, pp. 324-332
Closed Access
Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression
Lei Xia, Ya Ni Gou, Jin Yong Hao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
GOLPH3 Participates in Mitochondrial Fission and Is Necessary to Sustain Bioenergetic Function in MDA-MB-231 Breast Cancer Cells
Catalina M. Polanco, Viviana A. Cavieres, Abigail J. Galarza, et al.
Cells (2024) Vol. 13, Iss. 4, pp. 316-316
Open Access | Times Cited: 3
Demethylzeylasteral induces PD-L1 ubiquitin–proteasome degradation and promotes antitumor immunity via targeting USP22
Yanyan Zhang, Yun Huang, Dianping Yu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4312-4328
Open Access | Times Cited: 3
Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano‐Delivery Systems for Enhanced Immunotherapy
Xin Huang, Weiyue Zhang
Small Methods (2023) Vol. 8, Iss. 8
Closed Access | Times Cited: 6
GLT8D2 is a prognostic biomarker and regulator of immune cell infiltration in gastric cancer
Han Wang, Jiabin Zheng, Qingyang Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
Shanshan Zhong, Xiaoling Liu, Tomonori Kaneko, et al.
Cells (2024) Vol. 13, Iss. 14, pp. 1193-1193
Open Access | Times Cited: 1
Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer
Wei Wang, Min Kong, Fu Shen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Redundancy and absurd names in immunology
Piotr Kuśnierczyk
International Journal of Immunogenetics (2024) Vol. 51, Iss. 3, pp. 125-129
Open Access
The Sweet and Sour of Glycan Targeting in Cancer
Guillermina Rado, Santiago A. Rodríguez-Zraquia, Pablo Lores, et al.
Interdisciplinary cancer research (2024)
Closed Access
Research progress on S-palmitoylation modification mediated by the ZDHHC family in glioblastoma
Bo Tang, Wei Kang, Qiang Dong, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access
Perspectives on molecular mechanisms of post-translational modification and their functional influence on certain diseases
Damdinbazar Dolgion, Byambajav Bolortuya, Nomuun Oyunbat, et al.
Proceedings of the Institute of Biology (2023) Vol. 39, Iss. 1, pp. 9-29
Open Access
Page 1

Scroll to top